Knockdown of microRNA-203 reduces cisplatin chemo-sensitivity to osteosarcoma cell lines MG63 and U2OS in vitro by targeting RUNX2

References

• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–43.
   PubMed Web of Science ®Google Scholar
• Zhou G, Shi X, Zhang J, Wu S, Zhao J. MicroRNAs in osteosarcoma: from biological players to clinical contributors, a review. J Int Med Res. 2013;41(1):1–12.
   PubMed Web of Science ®Google Scholar
• Poletajew S, Fus L, Wasiutyński A. Current concepts on pathogenesis and biology of metastatic osteosarcoma tumors. Ortop Traumatol Rehabil. 2011;13(6):537–45.
   PubMedGoogle Scholar
• Chen R, Wang G, Zheng Y, Hua Y, Cai Z. Drug resistance-related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies. J Cell Mol Med. 2019;23(4):2280–92.
   PubMed Web of Science ®Google Scholar
• Liao YX, Yu HY, Lv JY, Cai YR, Liu F, He ZM, et al. Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma. Int J Oncol. 2019;55(6):1213–22.
   PubMed Web of Science ®Google Scholar
• Wang Y, Deng X, Yu C, Zhao G, Zhou J, Zhang G, Li M, Jiang D, Quan Z, Zhang Y. Synergistic inhibitory effects of capsaicin combined with cisplatin on human osteosarcoma in culture and in xenografts. J Exp Clin Cancer Res. 2018;37(1):251.
   PubMedGoogle Scholar
• Patil SL, Palat A, Pan Y, Rajapakshe K, Mirchandani R, Bondesson M, et al. MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin. Sci Rep. 2019;9(1):19089.
   PubMedGoogle Scholar
• Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029–35.
   PubMed Web of Science ®Google Scholar
• Tang QX, Wang LC, Wang Y, Gao HD, Hou ZL. Efficacy of methotrexate, doxorubicin, and cisplatin for osteosarcoma: Study protocol for a systematic review of randomized controlled trial. Medicine (Baltimore)). 2019;98(6):e14442.
   PubMed Web of Science ®Google Scholar
• Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6(7):1075–85.
   PubMed Web of Science ®Google Scholar
• Lilienthal I, Herold N. Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: A review of current and future strategies. IJMS. 2020;21(18):6885.
   Google Scholar
• Topping RP, Wilkinson JC, Scarpinato KD. Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling. J Biol Chem. 2009;284(21):14029–39.
   PubMed Web of Science ®Google Scholar
• Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB, Menck CFM. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo)). 2018;73(suppl 1):e478s.
   PubMedGoogle Scholar
• Cao X, Hou J, An Q, Assaraf YG, Wang X. Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updat. 2020;49:100671.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.
   PubMed Web of Science ®Google Scholar
• Shukla GC, Singh J, Barik S. MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011;3(3):83–92.
   PubMedGoogle Scholar
• Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science. 2005;310(5755):1817–21.
   PubMed Web of Science ®Google Scholar
• Pasquinelli AE, Hunter S, Bracht J. MicroRNAs: A developing story. Curr Opin Genet Dev. 2005;15(2):200–5.
   PubMed Web of Science ®Google Scholar
• Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci USA. 2007;104(23):9667–72.
   PubMed Web of Science ®Google Scholar
• Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847–65.
   PubMed Web of Science ®Google Scholar
• Ma G, Song G, Zou X, Shan X, Liu Q, Xia T, et al. Circulating plasma microRNA signature for the diagnosis of cervical cancer. Cancer Biomark. 2019;26(4):491–500.
   PubMed Web of Science ®Google Scholar
• Song YD, Li DD, Guan Y, Wang YL, Zheng J. miR-214 modulates cisplatin sensitivity of osteosarcoma cells through regulation of anaerobic glycolysis. Cell Mol Biol (Noisy-le-Grand)). 2017;63(9):75–9.
   PubMed Web of Science ®Google Scholar
• Hua Y, Jin Z, Zhou F, Zhang YQ, Zhuang Y. The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity. Eur Rev Med Pharmacol Sci. 2017;21(13):2989–94.
   PubMed Web of Science ®Google Scholar
• Zou Y, Yang J, Wu J, Luo C, Huang Y. miR-133b induces chemoresistance of osteosarcoma cells to cisplatin treatment by promoting cell death, migration and invasion. Oncol Lett. 2018;15(1):1097–102.
   PubMed Web of Science ®Google Scholar
• Zhou G, Lu M, Chen J, Li C, Zhang J, Chen J, et al. Identification of miR-199a-5p in serum as noninvasive biomarkers for detecting and monitoring osteosarcoma. Tumour Biol. 2015;36(11):8845–52.
   PubMedGoogle Scholar
• Wang F, Yu D, Liu Z, Wang R, Xu Y, Cui H, et al. MiR-125b Functions as a Tumor Suppressor and Enhances Chemosensitivity to Cisplatin in Osteosarcoma. Technol Cancer Res Treat. 2016;15(6):NP105–12.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Tang J, Wang J, Duan G, Zhou L, Zhou X. MiR-138 acts as a tumor suppressor by targeting EZH2 and enhances cisplatin-induced apoptosis in osteosarcoma cells. PLoS One. 2016;11(3):e0150026.
   PubMed Web of Science ®Google Scholar
• Chang JH, Hwang YH, Lee DJ, Kim DH, Park JM, Wu HG, et al. MicroRNA-203 modulates the radiation sensitivity of human malignant glioma cells. Int J Radiat Oncol Biol Phys. 2016;94(2):412–20.
   PubMed Web of Science ®Google Scholar
• Chi Y, Jin Q, Liu X, Xu L, He X, Shen Y, et al. miR-203 inhibits cell proliferation, invasion, and migration of non-small-cell lung cancer by downregulating RGS17. Cancer Sci. 2017;108(12):2366–72.
   PubMed Web of Science ®Google Scholar
• Wang B, Li X, Zhao G, Yan H, Dong P, Watari H, et al. miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway. J Exp Clin Cancer Res. 2018;37(1):235.
   PubMedGoogle Scholar
• Shen J, Zhang J, Xiao M, Yang J, Zhang N. miR-203 suppresses bladder cancer cell growth and targets Twist1. Oncol Res. 2018;26(8):1155–65.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jin S, Tan S, Shen Q, Xue Y. MiR-203 acts as a radiosensitizer of gastric cancer cells by directly targeting ZEB1. Onco Targets Ther. 2019;12:6093–104.
   PubMed Web of Science ®Google Scholar
• Cheng R, Lu C, Zhang G, Zhang G, Zhao G. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1. Oncol Rep. 2017;37(4):2129–36.
   PubMed Web of Science ®Google Scholar
• Fanelli M, Tavanti E, Patrizio MP, Vella S, Fernandez-Ramos A, Magagnoli F, et al. Cisplatin resistance in osteosarcoma: In vitro validation of candidate DNA repair-related therapeutic targets and drugs for tailored treatments. Front Oncol. 2020;10:331.
   PubMed Web of Science ®Google Scholar
• Lin W, Zhu X, Yang S, Chen X, Wang L, Huang Z, et al. MicroRNA-203 inhibits proliferation and invasion, and promotes apoptosis of osteosarcoma cells by targeting Runt-related transcription factor 2. Biomed Pharmacother. 2017;91:1075–84.
   PubMed Web of Science ®Google Scholar
• Jeong HI, Lee MJ, Nam W, Cha IH, Kim HJ. Osteosarcoma of the jaws in Koreans: Analysis of 26 cases. J Korean Assoc Oral Maxillofac Surg. 2017;43(5):312–7.
   PubMed Web of Science ®Google Scholar
• Xu JQ, Zhang WB, Wan R, Yang YQ. MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9. Tumour Biol. 2014;35(10):9847–53.
   PubMedGoogle Scholar
• Iwasaki T, Tanaka K, Kawano M, Itonaga I, Tsumura H. Tumor-suppressive microRNA-let-7a inhibits cell proliferation via targeting of E2F2 in osteosarcoma cells. Int J Oncol. 2015;46(4):1543–50.
   PubMed Web of Science ®Google Scholar
• Lian D, Wang ZZ, Liu NS. MicroRNA-1908 is a biomarker for poor prognosis in human osteosarcoma. Eur Rev Med Pharmacol Sci. 2016;20:1258–62.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Duan G, Feng S. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1. Biochem Biophys Res Commun. 2015;459(3):367–73.
   PubMed Web of Science ®Google Scholar
• Yang J, Guo W, Wang L, Yu L, Mei H, Fang S, et al. Cisplatin-resistant osteosarcoma cells possess cancer stem cell properties in a mouse model. Oncol Lett. 2016;12(4):2599–605.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257
   PubMed Web of Science ®Google Scholar
• Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27–36.
   PubMed Web of Science ®Google Scholar
• Cocetta V, Ragazzi E, Montopoli M. Mitochondrial involvement in cisplatin resistance. IJMS. 2019;20(14):3384.
   Google Scholar
• Keremu A, Aini A, Maimaitirexiati Y, Liang Z, Aila P, Xierela P, et al. Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1alpha. Biosci Rep. 2019;39:BSR20170080.
   PubMed Web of Science ®Google Scholar
• Niveditha D, Mukherjee S, Majumder S, Chowdhury R, Chowdhury S. A global transcriptomic pipeline decoding core network of genes involved in stages leading to acquisition of drug-resistance to cisplatin in osteosarcoma cells. Bioinformatics. 2019;35(10):1701–11.
   PubMed Web of Science ®Google Scholar
• Song L, Duan P, Gan Y, Li P, Zhao C, Xu J, et al. Silencing LPAATβ inhibits tumor growth of cisplatin-resistant human osteosarcoma in vivo and in vitro . Int J Oncol. 2017;50(2):535–44.
   PubMed Web of Science ®Google Scholar
• Kim M, Jung JY, Choi S, Lee H, Morales LD, Koh JT, et al. GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy. Autophagy. 2017;13(1):149–68.
   PubMed Web of Science ®Google Scholar
• Zheng D, Wu W, Dong N, Jiang X, Xu J, Zhan X, et al. Mxd1 mediates hypoxia-induced cisplatin resistance in osteosarcoma cells by repression of the PTEN tumor suppressor gene. Mol Carcinog. 2017;56(10):2234–44.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang Z, Zhang L, Zhong Z. Cytoplasmic APE1 promotes resistance response in osteosarcoma patients with cisplatin treatment. Cell Biochem Funct. 2020;38(2):195–203.
   PubMed Web of Science ®Google Scholar
• Song L, Duan P, Gan Y, Li P, Zhao C, Xu J, et al. MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATβ in osteosarcoma. Braz J Med Biol Res. 2017;50(5):e6359.
   PubMed Web of Science ®Google Scholar
• Yu WC, Chen HH, Qu YY, Xu CW, Yang C, Liu Y. MicroRNA-221 promotes cisplatin resistance in osteosarcoma cells by targeting PPP2R2A. Biosci Rep. 2019;39:BSR20190198.
   Web of Science ®Google Scholar
• Ru P, Steele R, Hsueh EC, Ray RB. Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer. 2011;2(7):720–7.
   PubMedGoogle Scholar
• Zhang X, Zhang Y, Liu X, Fang A, Li P, Li Z, et al. MicroRNA-203 is a prognostic indicator in bladder cancer and enhances chemosensitivity to cisplatin via apoptosis by targeting Bcl-w and survivin. PLoS One. 2015;10(11):e0143441.
   PubMed Web of Science ®Google Scholar
• Lin J, Lin Y, Fan L, Kuang W, Zheng L, Wu J, et al. miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer. Biochem Biophys Res Commun. 2016;473(2):382–7.
   PubMed Web of Science ®Google Scholar
• You HY, Xie XM, Zhang WJ, Zhu HL, Jiang FZ. Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203. In Vitro Cell Dev Biol Anim. 2016;52(8):857–63.
   PubMed Web of Science ®Google Scholar
• Xie Y, Sun W, Deng Z, Zhu X, Hu C, Cai L. MiR-302b suppresses osteosarcoma cell migration and invasion by targeting Runx2. Sci Rep. 2017;7(1):13388.
   PubMedGoogle Scholar
• Sadikovic B, Thorner P, Chilton-Macneill S, Martin JW, Cervigne NK, Squire J, et al. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer. 2010;10:202
   PubMed Web of Science ®Google Scholar
• Roos A, Satterfield L, Zhao S, Fuja D, Shuck R, Hicks MJ, et al. Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis. Br J Cancer. 2015;113(9):1289–97.
   PubMed Web of Science ®Google Scholar
• Ling Z, Fan G, Yao D, Zhao J, Zhou Y, Feng J, et al. MicroRNA-150 functions as a tumor suppressor and sensitizes osteosarcoma to doxorubicin-induced apoptosis by targeting RUNX2. Exp Ther Med. 2020;19(1):481–8.
   PubMed Web of Science ®Google Scholar
• Wang XX, Ye FG, Zhang J, Li JJ, Chen QX, Lin PY, et al. Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2. Cancer Manag Res. 2018;10:4393–400.
   PubMed Web of Science ®Google Scholar
• Xie J, Yu F, Li D, Zhu X, Zhang X, Lv Z. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2. Tumour Biol. 2016;37(1):1197–204.
   PubMedGoogle Scholar